COST-EFFECTIVENESS OF RANIBIZUMAB VERSUS AFLIBERCEPT IN TREATMENT OF TREATMENT OF VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR OEDEMA (DMO)

被引：0
|
作者：
Haig, J. [1 ]
Regnier, S. A. [2 ]
Malcom, W. [3 ]
Xue, W. [4 ]
机构：
[1] Optum, Burlington, ON, Canada
[2] Novartis AG, Basel, Switzerland
[3] Novartis UK LTD, Frimley Camberley, Surrey, England
[4] Optum, Uxbridge, Middx, England
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2132
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS34
引用
收藏
页码：A609 / A609
页数：1
相关论文
共 50 条
  • [21] Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema
    Bandello, Francesco
    De Benedetto, Umberto
    Knutsson, Karl Anders
    Parodi, Maurizio Battaglia
    Cascavilla, Maria Lucia
    Iacono, Pierluigi
    CLINICAL OPHTHALMOLOGY, 2011, 5 : 1303 - 1308
  • [22] A UK COST-MINIMISATION ANALYSIS OF BROLUCIZUMAB VERSUS AFLIBERCEPT IN DIABETIC MACULAR OEDEMA (DMO)
    Sydnor, S.
    Ibrahim, M.
    Sing, I
    Vudumula, U.
    Marshall, L.
    Hancock, E.
    Bandeiras, C.
    Felizzi, F.
    VALUE IN HEALTH, 2022, 25 (12) : S135 - S135
  • [23] Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
    Vandekerckhove, Kristof R. O. A.
    INTERNATIONAL OPHTHALMOLOGY, 2015, 35 (04) : 603 - 609
  • [24] Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
    Kristof ROA Vandekerckhove
    International Ophthalmology, 2015, 35 : 603 - 609
  • [25] Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis
    Sydnor, Shelby
    Chatterjee, Swarnendu
    Cooney, Philip
    Kaur, Simarjeet
    Macmillan, Tom
    Stewart, Daisy
    Munro, Isobel
    Bandeiras, Catia
    Paine, Abby
    Felizzi, Federico
    DIABETES THERAPY, 2023, 14 (07) : 1193 - 1216
  • [26] Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis
    Shelby Sydnor
    Swarnendu Chatterjee
    Philip Cooney
    Simarjeet Kaur
    Tom Macmillan
    Daisy Stewart
    Isobel Munro
    Cátia Bandeiras
    Abby Paine
    Federico Felizzi
    Diabetes Therapy, 2023, 14 : 1193 - 1216
  • [27] PROGNOSTIC FACTORS IN THE TREATMENT OF DIABETIC MACULAR OEDEMA (DMO) USING AFLIBERCEPT, RANIBIZUMAB AND BEVACIZUMAB (DRCR.NET PROTOCOL T)
    Gerendas, B. S.
    Bogunoivic, H. B.
    Schlegl, T.
    Sadeghipour, A.
    Waldstein, S. M.
    Schmidt-Erfurth, U.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2016, 26 (04) : E89 - E89
  • [28] OUTCOMES OF SWITCHING TREATMENT TO AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR OEDEMA REFRACTORY TO RANIBIZUMAB
    Konidaris, V. E.
    Tsaousis, K. T.
    Al-Hubeshy, Z.
    Pieri, K.
    Deane, J.
    Empeslidis, T.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2017, 27 (02) : E84 - E84
  • [29] ANALYSIS OF COST-EFFECTIVENESS OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS AFLIBERCEPT IN THE TREATMENT OF VISUAL SECONDARY LOSS TO DIABETIC MACULAR EDEMA FROM THE PERSPECTIVE OF THE HEALTH SYSTEM IN COLOMBIA
    Karpf, E.
    Sanchez-Thorin, J. C.
    VALUE IN HEALTH, 2015, 18 (07) : A881 - A881
  • [30] RELIGHT- RANIBIZUMAB TREATMENT OF DIABETIC MACULAR OEDEMA (DMO) WITH BIMONTHLY MONITORING AFTER INITIAL TREATMENT
    Pearce, I.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2013, 23 (03) : 460 - 460
12345